In locally advanced prostate cancer with bladder invasion, frequently encountered problems such as bleeding, urinary retention, hydronephrosis, and pain create distress for the patients. Therefore patients' quality of life is disrupted and duration of hospitalization is prolonged. Relevant literature about accurate staging and treatment of locally advanced prostate cancer with bladder invasion was investigated. Locally advanced prostate cancer can present as a large-volume aggressive tumor extending beyond boundaries of prostate gland, and involving neighboring structures which can be involved as recurrence(s) following initial local therapy. Survival times of these patients can range between 5 and 8 years. Their common characteristics are adverse and severe local symptoms unfavorably affecting quality of life Control of local symptoms and their effective palliation are independent clinical targets influencing survival outcomes of these patients. The treatment outcomes of locally advanced prostate cancer into the bladder are currently debatable. Although in the current TNM classification, it is defined in T4a, we think that this may be categorized as a subgroup of T3 and thus encourage surgeons for the indication of radical surgeries (radical prostatectomy, radical cystoprostatectomy) in selected patient populations after discussing issues concerning consequences of the treatment alternatives, and expectations with the patients. Cystoprostatectomy followed by immediate androgen deprivation therapy may be a feasible option for selected patients with previously untreated prostate cancer involving the bladder neck because of excellent local control and long term survival. 
its incidence ranges between 5-15% (2) . Approximately 5-15% of the PC cases are located in clinical stage of T4. In current TNM staging, bladder neck invasion (BNI) has been categorized as stage T4 disease ( Table 1) . Management of localized PC and metastatic disease has been summarized in algorithms, although optimal treatment of clinical stage T3-T4N0M0 PC is intensively debated. One of the main reasons of these debates is related to inaccurate local clinical staging over T2 or under staging of positive lymph node (LN) (3) . According to European Association of Urology (EAU) guidelines, watchful-waiting, radiotherapy (RT), radical retropubic prostatectomy (RRP), androgen deprivation therapy (ADT) and various combinations of these treatment modalities based on general clinical condition of the patient and local invasion of the tumor can be used (Table  2) . According to the current scientific data, multimodality therapy was recommended for the majority of patients. Treatment of locally advanced disease aims at two fundamental goals; the first goal is complete elimination of the disease and the second one is achievement of local control. In terms of biological behavior of PC, low, medium and high risk groups are defined. For high-risk disease, 'clinical T3', 'locally advanced', 'bad differentiated' terms are used and however these are not sufficient to identify the disease (4) . Definition of high-risk PC is associated with different criteria according to different sources as summarized in Table 3 . D'Amico risk classification grouping is the most widely used. Accordingly, prostate-specific antigen (PSA) ≥ 20 ng/mL or Gleason score (GS) 8-10 or clinical stage ≥ cT2 are considered as high-risk criteria of prostate cancer (5) . American Urological Association (AUA) has also used this risk stratification since 2007 (6) . Traditionally, urologists prefer RT and ADT rather than RRP for the treatment of high risk PC. Population-based Surveillance, Epidemiology and End Results (SEER) cancer data examination results showed us that in clinical T3 disease the rate of patients who underwent RRP, decreases from 18.1 to 9.1% and RT rates increase of 20% (7) . In patients under the age of 70 who were diagnosed with high-risk prostate cancer, 25% of them could not receive an effective local treatment (2) . According to the Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) data, most of the newly diagnosed patients with highrisk localized PC canalize to the ADT as if the unique
INTRODUCTION
Locally advanced prostate cancer (LAPC) has been clinically described as a cancer extending beyond prostate capsule, with invasion of pericapsullar tissue, apical region of the bladder, bladder neck or seminal vesicles without lymph node involvement or distant metastases. In clinical staging, they are categorized as T3-T4 N0 M0 prostate cancer (PC) and constitute 10-20% of the cases with newly diagnosed cases of PC (1) . While in previous reports, nearly 40% of the cases with newly diagnosed PC were categorized in clinical stage T3 (cT3), currently 
Radiotherapy
T3NoMo In the early postoperative period in patients with adjuvant RT [positive surgical margins, especially in the] progression-free survival helpful 1 T2-T3NoMo, in patients with persistent elevated PSA recurrence of elevated PSA and PSA 0.5 ng ml before RT can be given in recovery 3 T3-T4NoMo ve WHO performance status-2 for patients; concomitant and adjuvant hormone therapy [3 yr ] is beneficial to overall survival 1 T2c-T3 No-x, Gleason 2-6 in patients neo-adjuvant and concurrent with short term ADT overall survival was helpful 1b High-risk N1Mo and without severe comorbidities in patients pelvic external beam RT and concurrent long-term adjuvant hormone therapy, overall survival, biochemical control is useful, due to disease and the development of metastases associated with failure delays 2b
Hormonotherapy Symptomatic, T3-T4, PSA > 25-50 ng mL, PSA doubling time < 1 year for patients 1 Patients suitable for RT are not suitable for hormonal monotherapy Nonsteroidal antiandrogen monotherapy is an alternative to castration 2a Table 2 . 2013 EAU guidelines in the light of the treatment of locally advanced PC, some of the alternatives. (6) PSA 20-100 ng/ml, biopsy GS 8-10 and Any clinical stage or clinical stage ≥ T2c or PSA < 100 ng/ml and GS8-10 NCCN (7) PSA > 20 ng/ml or GS 8-10 or clinical stage ≥ T3 or T2b/c, GS = 7, PSA > 10 any two of the parameters Eastham et al. (8) Kattan nomograms in the 5-year progression probability ≤ 50% D'Amico et al. (9) Preoperative PSA velocity > year 2 ng/ml (15) . In this study, 10 and 15 year disease-free survival rates of 296 (76%) patients with SVI but no LN involvement were reported as 89 and 81%, respectively. However their biochemical recurrence rates were indicated as 64 and 68%, respectively. In the same study, 10-year biochemical disease-free and disease-specific survival rates for 92 patients with SVI and LN involvement were reported respectively as 10 and 74%. Nevertheless, at the end of 10 years, 66% of the patients were still surviving (7). Masterson et al. analyzed 24 patients with LN positivity and SVI and reported 5-year biochemical disease-free survival rate as 25.9% and they estimated mean time interval up to the PSA progression as 6 months (16). Boorjian indicated that in cases with only one LN involvement, the risk of disease-specific mortality had increased 4-fold which was two times higher in patients with multiple LN involvement (17) . In a higher-stage LAPC, as supported by the outcomes of some literature studies, extended LN dissection can be recommended instead of standard pelvic LN dissection. In standard pelvic LN dissection, lymphadenectomy is confined within obturator fossa, whereas in the extended approach, whose importance has been currently emphasized in many publications, in addition to the boundaries of the standard procedure, the target of lymphadenectomy is extended to include external iliac vein, internal iliac vessels, and femoral canal. In a study conducted by Heidenreich et al., the Authors reported that LN positivity had been 12% in patients who had undergone standard pelvic LN dissection, but it had raised up to 26% in the extended procedure. For high-risk patients as those with BNI, extended pelvic LN dissection has been recommended, because, especially in the presence of low-volume, micrometastatic LN involvement, relatively longer disease-free survival can be achieved (18) . Morbidity of RRP in high-risk PC is similar to that in low-risk patients (4) . For these reasons, nowadays RRP in high-risk patients began to be proposed and implemented more frequently. Berglund et al. reported that in patients of high-risk groups who underwent RRP; recovery time, duration of catheterization and continence turnaround time were similar with patients of low risk group (19) . In RRP patients with clinical T3, perioperative mortality rates were similar with clinical T2 patients (20) . In major centers RRP results of the 5-year and 10-year biochemical recurrence free rates were 30-70% and 15-60%, respectively (21) (22) . In another study, clinical T1c-T3b PC patients who underwent RRP or RT were retrospectively compared. At 8-year follow-up results when poor-risk patients treated with RRP were compared to those treated with RT showed that metastatic progression rate of RT group was 9.5% more than to RRP group (4). One of the most important advantage in RRP is the ability to accurate pathological staging. Approximately 15-25% of the clinical stage T3 tumors reported as highgraded (23) . Consequently RRP may provide more information in determining the need for additional treatment.
In addition, LN dissection that was performed during RRP helps us to detect micrometastases which cannot be detected by imaging methods. Otherwise; removal of the seminal vesicles increases the effectiveness of adjuvant treatment (23) . In high-risk patients, considering age, general health status and 10 year life expectation, RRP should be recommended as primary treatment. Ten-year biochemical recurrence-free survival rate was 68% in 35% of 175 RRP patients who were reported as organconfined disease according to D'Amico risk classification and at the end of follow-up, metastasis-free survival rate and cancer-specific survival rate were 84% and 92%, respectively (24) . In a retrospective multicenter study, 3828 patients with high risk of PC who underwent RRP were evaluated between years of 1987 and 2010. Ten-year cancer-specific and non-cancer-cause mortality rates were 5.9% and 14.3%, respectively (25) . In a multicenter European study, were evaluated 1366 patients who were diagnosed as high-risk PC (26) . In 37% of overall patients, organ-confined disease has been identified. This rate in presence of only one of the preoperative risk factor was 45%, but in presence of three risk factors (GS, PSA, clinical stage) organ-confined disease detection rate dropped to 9%. Fowler et al. reported that the 5-year survival rate of patients with LAPC who were treated with hormone therapy alone was 92% with a mean follow-up of 78 months (27) . Bolla et al. compared the results of combined ADT and RT with those of RT alone in LAPC and reported that overall survival at 5 years was 79% in the combination group and 62% in the RT alone group (28) . However, patients with PC BNI were generally highgrade (GS 9-10). In the majority of patients short time to progression and lower urinary tract symptoms were observed. We know the high incidence of complications that occurr when salvage surgery performed after RT (29) (30) (31) . Furthermore, the study indicated the survival of RRP over combined RT with ADT for clinical T4 PC with lymph node metastases (32) . When performing cystoprostatectomy (CP) for PC involving the bladder neck, the possibility of overtreatment should be considered. Among clinical T4, compared to patients with PC involving the rectum or pelvic floor muscles, those with BNI may be better candidates for CP to achieve local cancer control and improvement of quality of life (QOL).
Manifestations of BI consist of hematuria, urinary urgency, pelvic pain, and bladder outlet obstruction. Besides, bladder outlet or ureteral obstruction can lead to renal failure. Many patients might be dependent on lifelong requirement for nephrostomy tubes, ureteral, and urethral stents, and more than one invasive procedure might be needed for routine tube replacements or revision operations. Complications of long-term tube drainage of the urinary tract comprise obstruction, bladder spasms, bleeding, infection, and stone formation. Local symptoms related to BI determine quality of life and reveals the clinical condition. Among adjuvant procedures applied for the management of locally advanced and symptomatic PC patients, systemic treatments as ADT and chemotherapy, local therapies including cryotherapy or surgery (TUR), and local palliative approaches (nephrostomy, and ureteral stent implantation) can be enumerated. The beneficial effect of androgen therapy is restricted with the development of androgen insensitivity. Still, in 89% of the patients under systemic chemotherapy, local symptoms were maintained (1). Cryotherapy has been tried after failure of RT, but could not prevent lower urinary tract symptoms (33) . On the other hand relieve of outlet obstruction by transurethral resection (TUR) is short-lasting and repeated transurethral procedures might be required (34) . Previous reports on patients who had undergone salvage surgery including CP have demonstrated that they have rarely provided cure. However, in these reports palliative role of CP on patients with local symptoms was not investigated. Leibovici et al. performed palliative CP on a total of 38 T4 PC patients who developed recurrence following primary disease (n = 17), and RT (n = 21). The authors compared local symptoms, and the need for surgical intervention for the relief of obstruction before the operation, and at postoperative 3 month follow up during a mean follow-up period of 23 months (35) showing that the role of palliative CP was not statistically significant. (36) .
In the light of these data, we need further researches in order to achieve a more accurate assessment and alternative treatments for LAPC patients.
